Trials / Unknown
UnknownNCT05617430
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
An Exploratory Study to Evaluate the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine With Sintilimab and Bevacizumab for BCLC-C Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with sintilimab and bevacizumab in the first line treatment of patients with BCLC-C hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HAIC | Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h. Q3W |
| DRUG | Sintilimab | 200mg IV d1, Q3W |
| DRUG | Bevacizumab Biosimilar IBI305 | 7.5mg/kg IV d1, Q3W |
Timeline
- Start date
- 2022-11-02
- Primary completion
- 2024-04-01
- Completion
- 2024-06-01
- First posted
- 2022-11-15
- Last updated
- 2022-11-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05617430. Inclusion in this directory is not an endorsement.